Neumora Therapeutics
NMRA
60 hedge funds and large institutions have $745M invested in Neumora Therapeutics in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 12 closing their positions.
183% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 12
61% more call options, than puts
Call options by funds: $359K | Put options by funds: $223K
58% more funds holding
Funds holding: 38 → 60 (+22)
45% more capital invested
Capital invested by funds: $512M → $745M (+$233M)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
4.81% more ownership
Funds ownership: 23.84% → 28.65% (+4.8%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Iconiq Capital
San Francisco,
California
|
+$41.7M |
| 2 |
BlackRock
New York
|
+$12.5M |
| 3 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
+$11.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.19M |
| 5 |
Goldman Sachs
New York
|
+$6.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soros Capital Management
New York
|
-$8.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.99M |
| 3 |
Millennium Management
New York
|
-$3.88M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.62M |
| 5 |
AG
Artal Group
Luxembourg
|
-$3.07M |
NMRA Hedge Fund Activity: Q4 2023 in Review
60 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q4 2023, worth a combined $745M — up 45% from $512M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new NMRA positions and 12 closed out — a net gain of 22 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Iconiq Capital, opening a new position worth an estimated $41.7M. The largest seller was Soros Capital Management, exiting entirely with an estimated $8.3M sold.
- 60 institutional investors held Neumora Therapeutics (NMRA) as of Q4 2023, up from 38 in Q3 2023.
- Funds reported $745M of Neumora Therapeutics stock for Q4 2023, up 45% quarter-over-quarter.
- 34 funds opened new Neumora Therapeutics positions in Q4 2023 and 12 closed out, a net change of +22 holders.
- The largest Neumora Therapeutics buyer in Q4 2023 was Iconiq Capital, an estimated $41.7M added.
- The largest Neumora Therapeutics seller in Q4 2023 was Soros Capital Management, an estimated $8.3M sold.
Based on aggregated 13F filings for Q4 2023.